Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire

05/13

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here).

A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635786609"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635786609\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635786609?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635786609","market":"sh","top_or_hot":-1,"title":"Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ","media":"GlobeNewswire","content":"<html><body><p>SAN MATEO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link <u>here</u>).</p> <p>A webcast of the fireside chat will be available in the Investors &amp; Media section of Sagimet’s website at <u>www.sagimet.com</u>, with an archived replay available for 90 days following the live event.</p> <p><strong>About Sagimet Biosciences </strong></p> <p>Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit <u>www.sagimet.com</u>.</p> <p><strong>Investor Contact:</strong><br/>Joyce Allaire <br/>LifeSci Advisors <br/><u>JAllaire@LifeSciAdvisors.com</u></p> <p><strong>Media Contact:</strong><br/>Maggie Whitney<br/>LifeSci Communications<br/><u>mwhitney@lifescicomms.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MTJhMTI5NTgtMDM0My00ZjFhLWIxNmItNWZkMjNlOGU4NThhLTEyMjAyMDEtMjAyNi0wNS0xMy1lbg==/tiny/Sagimet-Biosciences-Inc-.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2026-05-13 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>SAN MATEO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/SGMT\">Sagimet Biosciences Inc.</a> (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link <u>here</u>).</p> <p>A webcast of the fireside chat will be available in the Investors &amp; Media section of Sagimet’s website at <u>www.sagimet.com</u>, with an archived replay available for 90 days following the live event.</p> <p><strong>About Sagimet Biosciences </strong></p> <p>Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit <u>www.sagimet.com</u>.</p> <p><strong>Investor Contact:</strong><br/>Joyce Allaire <br/>LifeSci Advisors <br/><u>JAllaire@LifeSciAdvisors.com</u></p> <p><strong>Media Contact:</strong><br/>Maggie Whitney<br/>LifeSci Communications<br/><u>mwhitney@lifescicomms.com</u></p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/MTJhMTI5NTgtMDM0My00ZjFhLWIxNmItNWZkMjNlOGU4NThhLTEyMjAyMDEtMjAyNi0wNS0xMy1lbg==/tiny/Sagimet-Biosciences-Inc-.png\"/></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QDTE","symbol_name":"Roundhill N-100 0DTE Covered Call Strategy ETF","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293849/0/en/Sagimet-Biosciences-to-Participate-in-the-H-C-Wainwright-4th-Annual-BioConnect-Investor-Conference-at-NASDAQ.html","article_id":"2635786609","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635786609","pubTimestamp":1778670000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"SAN MATEO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","NDX":"纳斯达克100指数","TECS":"Direxion Daily Technology Bear 3X Shares","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","QYLG":"Nasdaq 100 Covered Call & Growth ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","FTEC":"Fidelity MSCI Information Techno","SQQQ":"纳指三倍做空ETF","SGMT":"Sagimet Biosciences Inc.","PSQ":"做空纳斯达克100指数ETF-ProShares","QLD":"2倍做多纳斯达克100指数ETF-ProShares","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","QQQM":"NASDAQ100指数ETF-Invesco","QID":"两倍做空纳斯达克指数ETF-ProShares","IYW":"美国科技ETF-iShares","ONEQ":"Fidelity NASDAQ Composite Index ETF","TQQQ":"纳指三倍做多ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4139":"生物科技","TQQY":"GraniteShares YieldBOOST QQQ ETF","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QQQ":"纳指100ETF",".IXIC":"NASDAQ Composite"},"translate_title":"Sagimet Biosciences将参加H.C.温赖特在纳斯达克举行的第四届BioConnect年度投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONEQ":0.6,"JEPQ":0.6,"TQQY":0.6,"QQQE":0.6,"QDTE":0.6,"QQQY":0.6,"QQQA":0.6,"NDX":0.6,"NQmain":0.6,"SQQQ":0.6,"GPIQ":0.6,"NVIW.SI":0.6,"TECS":0.6,"PSQ":0.6,"MNQmain":0.6,"SGMT":1.5,"IYW":0.6,"QQQM":0.6,".IXIC":1.5,"QID":0.6,"QYLG":0.6,"QQQ":0.6,"QLD":0.6,"TQQQ":0.6,"FTEC":0.6,"QQQJ":0.6},"content_text":"SAN MATEO, Calif., May  13, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here). A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event. About Sagimet Biosciences  Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com. Investor Contact:Joyce Allaire LifeSci Advisors JAllaire@LifeSciAdvisors.com Media Contact:Maggie WhitneyLifeSci Communicationsmwhitney@lifescicomms.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}